DK0881906T4 - Farmaceutisk sammensætning til immunmodulation, som er baseret på peptider og adjuvanser - Google Patents

Farmaceutisk sammensætning til immunmodulation, som er baseret på peptider og adjuvanser

Info

Publication number
DK0881906T4
DK0881906T4 DK97905068T DK97905068T DK0881906T4 DK 0881906 T4 DK0881906 T4 DK 0881906T4 DK 97905068 T DK97905068 T DK 97905068T DK 97905068 T DK97905068 T DK 97905068T DK 0881906 T4 DK0881906 T4 DK 0881906T4
Authority
DK
Denmark
Prior art keywords
adjuvants
peptides
pharmaceutical composition
immunomodulation based
immunomodulation
Prior art date
Application number
DK97905068T
Other languages
Danish (da)
English (en)
Other versions
DK0881906T3 (da
Inventor
Tamas Schweighoffer
Walter Schmidt
Max Birnstiel
Peter Steinlein
Michael Buschle
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27215945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0881906(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Priority claimed from DE19638313A external-priority patent/DE19638313C2/de
Priority claimed from DE19648687A external-priority patent/DE19648687A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK0881906T3 publication Critical patent/DK0881906T3/da
Publication of DK0881906T4 publication Critical patent/DK0881906T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DK97905068T 1996-02-24 1997-02-21 Farmaceutisk sammensætning til immunmodulation, som er baseret på peptider og adjuvanser DK0881906T4 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19638313A DE19638313C2 (de) 1996-09-19 1996-09-19 Pharmazeutische Zusammensetzung für die Immunmodulation
DE19648687A DE19648687A1 (de) 1996-11-25 1996-11-25 Pharmazeutische Zusammensetzung für die Immunmodulation
PCT/EP1997/000828 WO1997030721A1 (de) 1996-02-24 1997-02-21 Pharmazeutische zusammensetzung für die immunmodulation beruhend auf peptiden und adjuvantien

Publications (2)

Publication Number Publication Date
DK0881906T3 DK0881906T3 (da) 2004-12-20
DK0881906T4 true DK0881906T4 (da) 2009-05-25

Family

ID=27215945

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97905068T DK0881906T4 (da) 1996-02-24 1997-02-21 Farmaceutisk sammensætning til immunmodulation, som er baseret på peptider og adjuvanser

Country Status (35)

Country Link
US (1) US7105162B1 (ro)
EP (1) EP0881906B2 (ro)
JP (1) JP4184433B2 (ro)
KR (1) KR100457647B1 (ro)
CN (1) CN1177610C (ro)
AR (1) AR005945A1 (ro)
AT (1) ATE274350T1 (ro)
AU (1) AU722264B2 (ro)
BG (1) BG63682B1 (ro)
BR (1) BR9707694A (ro)
CA (1) CA2243559C (ro)
CO (1) CO4600681A1 (ro)
CZ (1) CZ295396B6 (ro)
DE (1) DE59711873D1 (ro)
DK (1) DK0881906T4 (ro)
EE (1) EE04481B1 (ro)
ES (1) ES2225951T5 (ro)
HK (1) HK1017257A1 (ro)
HR (1) HRP970100B1 (ro)
HU (1) HU224410B1 (ro)
ID (1) ID16038A (ro)
IL (1) IL125361A (ro)
MY (1) MY119276A (ro)
NO (1) NO983850L (ro)
NZ (1) NZ332020A (ro)
PE (1) PE55398A1 (ro)
PL (1) PL189413B1 (ro)
PT (1) PT881906E (ro)
RO (1) RO119344B1 (ro)
RS (1) RS50101B (ro)
SI (1) SI0881906T2 (ro)
SK (1) SK284582B6 (ro)
TR (1) TR199801649T2 (ro)
TW (1) TW585774B (ro)
WO (1) WO1997030721A1 (ro)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
JP4875799B2 (ja) * 1998-02-25 2012-02-15 アメリカ合衆国 Ａｄｐ−リボシル化外毒素により誘引される経皮免疫応答を促進するための皮膚浸透性エンハンサーおよびバリア崩壊剤の使用
DE69837350T2 (de) * 1998-04-20 2007-11-29 Torrey Pines Institute For Molecular Studies, San Diego Topische immunostimulierung zur induzierung der migration der langerhanszellen
EP2204186B1 (en) * 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
DE19909503A1 (de) * 1999-03-04 2000-09-07 Boehringer Ingelheim Int Tumorassoziiertes Antigen
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT409762B (de) * 2000-04-13 2002-11-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung von zytokin sekretierenden zellen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
KR20020014459A (ko) * 2000-08-18 2002-02-25 서진호 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
EP1347775B1 (en) * 2001-01-05 2016-11-30 Valneva Austria GmbH Uses for polycationic compounds as vaccine adjuvants
EP1347776A2 (en) * 2001-01-05 2003-10-01 Intercell Biomedizinische Forschungs- und Entwicklungs AG Anti-inflammatory use of polycationic compounds
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
US20050250716A1 (en) * 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US7528223B2 (en) 2002-07-24 2009-05-05 Intercell Ag Antigens encoded by alternative reading frames from pathogenic viruses
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP2314604A3 (en) 2002-10-15 2011-05-25 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
CN102512670A (zh) 2003-03-04 2012-06-27 英特塞尔股份公司 化脓链球菌抗原
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
WO2004087746A2 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
EP2298934A1 (en) 2003-04-15 2011-03-23 Intercell AG S. pneumoniae antigens
CA2522986A1 (en) 2003-05-07 2004-11-18 Intercell Ag Streptococcus agalactiae antigens i + ii
EP2267006A1 (en) 2003-05-30 2010-12-29 Intercell AG Enterococcus antigens
DE602004030343D1 (de) 2003-07-11 2011-01-13 Intercell Ag Hcv-vakzin
ES2297688T3 (es) 2004-03-12 2008-05-01 Intercell Ag Procedimiento para solubizar mezclas de peptidos.
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
PL1791858T3 (pl) 2004-09-24 2010-09-30 Intercell Ag Zmodyfikowane białko kapsydowe VP1 z parwowirusa B19
CN101048172A (zh) * 2004-10-29 2007-10-03 英特塞尔股份公司 用于慢性hcv患者的hcv疫苗
ES2396240T3 (es) * 2005-04-20 2013-02-20 Mitsuru Akashi Poliaminoácido para usar como adyuvante
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
CA2661224A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
EP2152731A2 (en) 2007-05-02 2010-02-17 Intercell AG Klebsiella antigens
KR100748265B1 (ko) * 2007-06-15 2007-08-10 (주)성문엔지니어링 공동주택에 배선된 전선의 합선방지구조
WO2008155291A2 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
ES2539818T3 (es) 2007-08-02 2015-07-06 Biondvax Pharmaceuticals Ltd. Vacunas contra la gripe multiepitópicas multiméricas
US8492331B2 (en) * 2008-03-27 2013-07-23 Nestec S.A. Methods for increasing absorption of peptides, peptidomimetics and other gastrointestinal transport protein substrates
CN102239253A (zh) 2008-12-03 2011-11-09 普罗蒂亚维仕尼科技有限公司 谷氨酰tRNA合成酶（GtS）片段
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
AU2010288239B2 (en) * 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
JP2013509963A (ja) 2009-11-09 2013-03-21 スポットライト テクノロジー パートナーズ エルエルシー 断片化ヒドロゲル
CN102695500A (zh) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 多糖基水凝胶
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
RU2478399C2 (ru) * 2011-06-16 2013-04-10 Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Российской академии сельскохозяйственных наук (ГНУ ВНИИБТЖ Россельхозакадемии) Способ получения специфического иммуномодулятора
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
JP6925980B2 (ja) 2015-05-13 2021-08-25 アジェナス インコーポレイテッド がんの処置および予防のためのワクチン
US20190080044A1 (en) * 2016-03-15 2019-03-14 Repertoire Genesis Incorporation Monitoring and diagnosis for immunotherapy, and design for therapeutic agent
US20200282032A1 (en) * 2016-05-27 2020-09-10 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
US11291718B2 (en) * 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
CN107469067B (zh) * 2017-09-05 2018-06-19 浙江大学 一种多肽及其改造体在制备免疫调节药物中的应用
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
CN110870912A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 亚甲蓝类染料作为疫苗佐剂的应用、包含该佐剂的疫苗及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (ro) 1968-05-31 1972-09-20
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4728639A (en) * 1982-07-27 1988-03-01 University Of Tennessee Research Corporation Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
BE1000587A4 (fr) * 1986-06-13 1989-02-14 Oncogen Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b.
EP0346022B1 (en) * 1988-06-10 1996-02-14 United Biomedical, Inc. Peptide fragments of HIV
ATE147633T1 (de) * 1988-10-27 1997-02-15 Univ Minnesota Immunhilfsmittel aus liposome enthaltend lymphokin il -2
WO1991009869A1 (en) 1990-01-05 1991-07-11 Medical Research Council Hiv-1 core protein fragments
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
EP1236473A3 (en) 1992-04-03 2003-01-15 The Regents Of The University Of California Self-assembling polynucleotide delivery system
JP3608788B2 (ja) 1992-08-31 2005-01-12 ルドヴィグ・インスティテュート・フォー・キャンサー・リサーチ Ｍａｇｅ−３遺伝子から誘導されてｈｌａ−ａ１により提示される単離されたノナペプチドおよびそれらの用途
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
CZ3000U1 (cs) * 1993-07-12 1995-02-22 Kufudakis Alekos Farmaceutický prostředek pro imunomodulační a adjuvantní léčbu
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
UY24367A1 (es) † 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria

Also Published As

Publication number Publication date
CO4600681A1 (es) 1998-05-08
EE9800255A (et) 1999-02-15
CZ295396B6 (cs) 2005-08-17
EP0881906B2 (de) 2009-02-04
RS50101B (sr) 2009-01-22
NO983850D0 (no) 1998-08-21
NZ332020A (en) 2000-02-28
HRP970100B1 (en) 2001-04-30
EP0881906B1 (de) 2004-08-25
BR9707694A (pt) 1999-07-27
DE59711873D1 (de) 2004-09-30
JP4184433B2 (ja) 2008-11-19
WO1997030721A1 (de) 1997-08-28
CA2243559C (en) 2011-08-09
PT881906E (pt) 2004-10-29
ID16038A (id) 1997-08-28
KR100457647B1 (ko) 2005-06-20
HUP9901186A2 (hu) 1999-07-28
US7105162B1 (en) 2006-09-12
AU722264B2 (en) 2000-07-27
TW585774B (en) 2004-05-01
BG102714A (en) 1999-06-30
IL125361A (en) 2002-08-14
CA2243559A1 (en) 1997-08-28
SK114598A3 (en) 1999-06-11
TR199801649T2 (xx) 1998-12-21
ATE274350T1 (de) 2004-09-15
KR19990082601A (ko) 1999-11-25
AR005945A1 (es) 1999-07-21
RO119344B1 (ro) 2004-08-30
EP0881906A1 (de) 1998-12-09
SI0881906T2 (sl) 2009-06-30
PL328455A1 (en) 1999-02-01
JP2000506125A (ja) 2000-05-23
NO983850L (no) 1998-10-21
HRP970100A2 (en) 1998-04-30
PL189413B1 (pl) 2005-08-31
YU6297A (sh) 1999-09-27
ES2225951T3 (es) 2005-03-16
DK0881906T3 (da) 2004-12-20
SK284582B6 (sk) 2005-07-01
CZ268998A3 (cs) 1999-07-14
PE55398A1 (es) 1998-09-22
HUP9901186A3 (en) 2001-01-29
CN1177610C (zh) 2004-12-01
IL125361A0 (en) 1999-03-12
SI0881906T1 (en) 2004-12-31
HK1017257A1 (en) 1999-11-19
ES2225951T5 (es) 2009-06-15
EE04481B1 (et) 2005-06-15
CN1211926A (zh) 1999-03-24
AU1875997A (en) 1997-09-10
BG63682B1 (bg) 2002-09-30
MY119276A (en) 2005-04-30
HU224410B1 (hu) 2005-08-29

Similar Documents

Publication Publication Date Title
DK0881906T4 (da) Farmaceutisk sammensætning til immunmodulation, som er baseret på peptider og adjuvanser
DK114797A (da) Farmaceutiske præparater til intranasal administrering
BR9710372B1 (pt) composto, e, composiÇço farmacÊutica.
DK1032555T3 (da) Cykliske aminosyrer og derivater deraf, som er anvendelige som lægemidler
NO991815L (no) Oksadiazoler, fremgangsmÕter for deres fremstilling og deres anvendelse som medikamenter
NO991130D0 (no) Modifiserte aminosyrer, farmas°ytiske preparater som inneholder disse forbindelsene og fremgangsmÕter for fremstilling derav
BR9608199B1 (pt) composição de vacina compreendendo um antìgeno, qs21 e um esterol.
NO995891L (no) LH-RH peptidanaloger, anvendelser og farmasoeytiske blandinger inneholdende disse
NO975513L (no) 3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse som legemiddel
NO985680L (no) Peptidderivater
DK1071433T3 (da) 2',2'-difluornucleosider til immunosuppressiv behandling og kombinationspræparater
ZA979573B (en) (Alpha-aminophosphino) peptide derivatives, process for their preparation and their therapeutic applications.
TR199500915A2 (tr) Peptidler.
NO983849D0 (no) Peptidderivater
NO983472D0 (no) Taxoider, deres fremstilling og farmas°ytiske preparater inneholdende taxoidene
HK1001404A1 (en) Isolated, tyrosinase derived peptides and uses thereof.
NO984444D0 (no) Benzothiofener, formuleringer som inneholder de samme, og fremgangsmÕter
NO995062D0 (no) <Beta>-anyloidpeptid-bindende proteiner og polynuldeotider som kodes for samme
NO901758L (no) Reninhemmende dipeptider, fremgangsmaate for deres fremstilling, midler som inneholder disse og deres anvendelse.
DE29607432U1 (de) Dichtbahn
ITGE960040A0 (it) Pentapeptide.
ES1036009Y (es) Vitrina de gases perfeccionada.
ITBO910215A1 (it) Compressore rotativo stellare per gas perfezionato.
DE69636231D1 (de) Menschliche chemokin-polypeptide.
IT241422Y1 (it) Valvola di sequenza.